Premium
A phase II trial of tamoxifen in hepatocellular carcinoma
Author(s) -
Engstrom Paul F.,
Levin Bernard,
Moertel Charles G.,
Schutt Allan
Publication year - 1990
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19900615)65:12<2641::aid-cncr2820651207>3.0.co;2-r
Subject(s) - medicine , tamoxifen , hepatocellular carcinoma , antiestrogen , oncology , carcinoma , gastroenterology , estrogen receptor , biopsy , estrogen , cancer , breast cancer
Because prolonged estrogen therapy can initiate hepatic adenomas, and estrogen receptors (ER) are found in 33% of hepatocellular carcinomas, a Phase II study of antiestrogen therapy was initiated in patients with hepatocellular carcinoma. Tamoxifen (20 mg twice a day) was administered to 33 patients who had biopsy proven and measurable hepatocellular carcinoma and who had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. No patient had a complete or partial antitumor response; eight patients had stable disease ranging from 5 to 13 months. The median survival time for all patients was 6 months from the initiation of tamoxifen therapy. Four patients have continuing long‐term survival of 18+, 22+, and 39+ months.